News

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

According to the company, the app features new content, including podcasts, discussion forums and downloadable content for eyecare professionals.

During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Managing dry eye requires addressing underlying disease process with therapy, treatments

This marks the first, in-person APAO congress since the COVID-19 pandemic

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

The agenda includes the Opening Ceremony, Women in Ophthalmology Luncheon, and Young Ophthalmologists’ Night, and that's only a sampling. The results of the APAO-Asia-Pacific Ocular Imaging Competition will also be announced.

According to the company, the formulations do not contain preservatives or boric acid and have a physiologic pH of 5.5. They also can be stored at room temperature for up to 180 days.

Saunders is returning to Bausch + Lomb after having served at the company as CEO from 2010 to 2013.

Saunders will return to Bausch + Lomb after having served at the company as CEO from 2010 to 2013.

The trial could prove to be a key development in the treatment of people with the rare inherited condition RP, which currently has no approved cure or standard treatment.

According to the companies, the collaboration will combine Formosa's APNT nanoparticle formulation platform with Eyenovia's Optejet dispensing technology for the development of new ophthalmic therapies in indications with significant unmet medical needs.

Andrew G. Lee, MD, has had direct experience as being an in-flight physician over 15 times on international and domestic flights and answers some of the most frequently asked questions about being the doctor on the plane.

A recent clinical study demonstrates that low intracranial pressure correlates with impaired patient visibility, especially in the nasal zone.

Sharing data between ophthalmologists, optometrists can lead to earlier diagnosis

The family-friendly conference, being held at the El Conquistador Resort in Puerto Rico, will promote women in the field, according to founder and program director Bonnie An Henderson, MD.

The family-friendly conference, being held at the El Conquistador Resort in Puerto Rico, will promote women in the field, according to founder and program director Bonnie An Henderson, MD.

The family-friendly conference, being held at the El Conquistador Resort in Puerto Rico, will promote women in the field, according to founder and program director Bonnie An Henderson, MD.

If approved by the FDA later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.

If approved later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.